In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.
Eli Lilly has entered a billion-dollar license agreement and research collaboration with Nimbus Therapeutics focused on developing oral obesity treatments. The deal includes an upfront payment and potential milestone payments, reinforcing Lilly’s aggressive expansion in the cardiometabolic space as competition intensifies around next-generation obesity therapies.
Hoth Therapeutics has filed multiple provisional patent applications aimed at expanding and protecting its product portfolio across several therapeutic programs. The filings are intended to strengthen the company’s intellectual property position as it advances early-stage assets and explores future partnering opportunities.
Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The move is designed to support growing demand for RNAi-based therapies and enhance the company’s long-term production capacity as its commercial portfolio continues to grow.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
